|
The Ampio class action lawsuit seeks to represent purchasers or acquirers of Ampio Pharmaceuticals, Inc. (NYSEAMERICAN: AMPE) common stock between December 29, 2020 and August 3, 2022, inclusive (the “Class Period”). The Ampio class action lawsuit – captioned Kain v. Ampio Pharmaceuticals, Inc., No. 22-cv-02105 (D. Colo.) – charges Ampio and certain of its top executive officers with violations of the Securities Exchange Act of 1934. If you suffered losses in Ampio stock and wish to serve as lead plaintiff of the Ampio class action lawsuit, please provide your information below. You can also contact Ampio Stock Loss Lawyer Timothy L. Miles by calling 855/846-6529 or via e-mail at tmiles@timmileslaw.com. Lead plaintiff motions for the Ampio class action lawsuit must be filed with the court no later than October 17, 2022. If you suffered losses in Ampio stock and have questions, please contact Ampio Stock Loss Lawyer Timothy L. Miles today.  Contact Ampio Stock Loss Lawyer Timothy L. Miles today Allegations in the Ampio Class Action LawsuitAmpio claims to have developed Ampion®, its lead product purportedly used to treat individuals with inflammatory conditions including, but not limited to, severe osteoarthritis of the knee (“OAK”). In June 2019, Ampio received a Special Protocol Assessment from the U.S. Food and Drug Administration (“FDA”) for an additional Phase III clinical trial titled “A Randomized, Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of an Intra-Articular Injection of Ampion in Adults with Pain Due to Severe Osteoarthritis of the Knee” (“AP-013”).The Ampio class action lawsuit alleges that defendants inflated Ampio’s true ability to successfully file a Biologics License Application for Ampion and inflated the results of the AP-013 study and the timing of unblinding the data from the AP-013 study. On April 20, 2022, Ampio issued a press release providing a regulatory update that the FDA had responded negatively to its Type C meeting request, disclosing the FDA’s conclusion that Ampio “should have sought FDA’s agreement on [certain] changes prior to analyzing and unblinding the data” and “FDA further stated that it did not agree that AP-013 could serve as a second pivotal trial for Ampion based on both the change in the analysis population and the analysis of pain only instead of the original prespecified co-primary endpoints.” On this news, Ampio’s stock price fell by more than 26%. Then, on May 16, 2022, Ampio announced that an independent special committee of the Board of Directors, with the assistance of independent legal counsel, was in the process of conducting an internal investigation relating to the AP-013 study. On this news, Ampio’s stock price fell an additional 10%. Finally, on August 3, 2022, Ampio revealed that certain defendants “and senior staff were aware, at the time of the per-protocol interim analysis in March 2020, that the AP-013 trial did not demonstrate efficacy for Ampion on its co-primary endpoints of pain and function; and that these Ampio executive offers and senior staff did not fully report the results of the AP-013 trial and the timing of unblinding of data from the AP-013 trial.” On this news, Ampio’s share price fell by more than 35%, further damaging investors who suffered losses in Ampio stock. The Lead Plaintiff Process in the Ampio Class Action LawsuitThe Private Securities Litigation Reform Act of 1995 permits any investor who purchased and suffered losses in Ampio to seek appointment as lead plaintiff in the Ampio class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the class action lawsuit. An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. If you suffered losses in Ampio stock, and have further questions, contact Ampio Stock Loss Lawyer Timothy L. Miles today. How Can a Ampio Stock Loss Lawyer Help Me?An Ampio Stock Loss Lawyer is well-versed in the complex laws that govern the securities industry and litigation. An Ampio Stock Loss Lawyer focuses on representing individual investors or funds who have been the victims of fraud or who have disputes with investment professionals. Ordinary individual investors, including civil servants, teachers, nurses, and retirees, may need a securities lawyer. In most cases, if they have lost money due to mistakes, incompetence, or fraud by an investment professional. While FINRA, the SEC, and state securities regulators serve a vital role in protecting investors, they simply have too many individuals, firms, and market transactions to monitor to discovery every act of fraud or negligence. Individual investors should consult with a securities lawyer if they have lost money due to fraud or stockbroker misconduct, such as an Ampio Stock Loss Lawyer who will work to recover the losses you sustained through an Ampio Class Action lawsuit. Contact an Ampio Stock Loss Lawyer if You Suffered Losses in Ampio StockIf you suffered losses in Ampio stock, contact Ampio Stock Loss Lawyer Timothy L. Miles today about a Ampio class action lawsuit, and see what a Ampio Stock Loss Lawyer can do for you. Timothy L. Miles, Esq.Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Mr. Miles was recentely selected by Martindale-Hubbell® and ALM as a 2022 Top Ranked Lawyer, 2022 Top Rated Litigator. and a 2022 Elite Lawyer of the South. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association, a superb rated attorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019). Mr. Miles has published over sixty articles on various issues of the law, including class actions, whistleblower cases, products liability, and more. Comments are closed.
|
Hours of Operation |
Contact InformationPhone: (855) Tim-M-Law (855-846-6529)
Email: tmiles@timmileslaw.com Website: www.classactionlawyertn.com Address:300 Centerview Dr., #247 Brentwood, TN 37027 (855) Tim-M-Law (855-846-6529)) |
